Kodai Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Kodai Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$9.51M	Buy	+85,958	New	+$10.9M	0.38%	83

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Kodai Capital Management's NBIX Position: Q1 2025 in Review

Kodai Capital Management opened a new position in Neurocrine Biosciences (NBIX) in Q1 2025: 85,958 shares worth $9.51M. The stake represents 0.38% of the portfolio and ranks #83 among its holdings.

586 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

Kodai Capital Management held 85,958 shares of Neurocrine Biosciences worth $9.51M as of Q1 2025.
Neurocrine Biosciences was a new Kodai Capital Management position in Q1 2025.
Neurocrine Biosciences made up 0.38% of Kodai Capital Management's portfolio in Q1 2025, its #83 holding.
586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Kodai Capital Management's 13F filing for Q1 2025, filed 15 May 2025.